A Single-case Design to Investigate a Compensatory Brain Game Supporting Goal Management Training Intervention in a Psychiatric Brain Injury Population
Launched by PROPERSONA · Apr 5, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to help people who have experienced acquired brain injuries and are dealing with issues like depression, anxiety, and difficulties in planning and organizing their daily tasks. The researchers want to see if a brain game, designed to support a well-known training method called Goal Management Training (GMT), can help improve the ability of patients to manage their goals and daily activities. GMT teaches patients how to break down tasks into smaller steps to make them easier to handle, and the brain game is meant to make this training more engaging and accessible.
To participate in this study, individuals must be between 18 and 75 years old, have a non-progressive acquired brain injury, and be receiving inpatient neuropsychiatric care. They also need to have some difficulties with executive function, which refers to skills like planning and problem-solving. Participants will undergo assessments to ensure they meet these criteria and will be expected to engage with the GMT training and the brain game over the course of the study. The trial aims to find out if this combination can help improve their daily functioning and reduce symptoms of depression and anxiety.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: 18 - 75 years
- • Non-progressive acquired brain injury
- • Minimal time post-onset of 3 months
- • Receive inpatient neuropsychiatric care at the time of inclusion
- • Executive deficits (neuropsychological assessment)
- • Reasonable amount of awareness in their deficits, at least to the extent that they are motivated and capable to learn new skills with respect to their executive performance.
- Exclusion Criteria:
- • Inability to speak/understand the Dutch language
- • Severe psychiatric disorders such as psychosis, manic episode, severe disruptive behavior
- • Neurodegenerative disorders (i.e. dementia, Huntington, Parkinson
- • Substance abuse (active)
- • Severe cognitive comorbidity (i.e. Korsakov)
- • Aphasia
- • Neglect
- • Unable to look at a computer screen for 15 minutes
- • Unable to operate a keyboard or computer mouse
About Propersona
Propersona is a pioneering clinical trial sponsor focused on advancing innovative therapeutics and digital health solutions. Committed to enhancing patient outcomes, Propersona leverages cutting-edge technology and a patient-centric approach to streamline the clinical trial process. With a robust portfolio of studies spanning various therapeutic areas, the organization emphasizes collaboration with healthcare professionals, regulatory bodies, and patients to ensure the successful development and delivery of novel treatments. Propersona is dedicated to fostering evidence-based practices that transform healthcare and improve the quality of life for individuals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wolfheze, Gelderland, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported